Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 2, 2010, Pages 151-158

  Capodanno, Davide ^a   Dharmashankar, Kodlipet ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

acute coronary syndromes; platelet; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; AR C124910 XX; CANGRELOR; CLOPIDOGREL; ESOMEPRAZOLE; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OMEPRAZOLE; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; UNCLASSIFIED DRUG; ADENOSINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PURINERGIC P2 RECEPTOR;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ATHEROSCLEROSIS; BLEEDING DISORDER; BRAIN HEMORRHAGE; CARDIOPULMONARY FUNCTION; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; HEART TAMPONADE; HEART VENTRICLE TACHYCARDIA; HEMARTHROSIS; HEMOPERICARDIUM; HUMAN; HYPOTENSION; HYPOVOLEMIC SHOCK; INTRAOCULAR HEMORRHAGE; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RETROPERITONEAL HEMORRHAGE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; THORAX PAIN; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; ANIMAL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; ADENOSINE; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; THROMBOSIS;

EID: 77951902652     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.172     Document Type: Review

References (41)

1. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 82, 47-59 (1990).
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
3. Mehta SR, Yusuf S, Peters RJ et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001).
4. Steinhubl SR, Berger PB, Mann JT 3rd et al.; CREDO investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411-2420 (2002).
5. Sabatine MS, Cannon CP, Gibson CM et al.; CLARITY-TIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352, 1179-1189 (2005).
6. Chen ZM, Jiang LX, Chen YP et al.; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607-1621 (2005).
7. Sabatine MS, Cannon CP, Gibson CM et al. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294, 1224-1232 (2005).
8. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102, 624-629 (2000).
9. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49, 1505-1516 (2007).
10. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb. Haemost. 102, 7-14 (2009).
11. Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am. Heart J. 156, S23-S28 (2008).
12. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 12, 443-447 (2001).
13. Angiolillo DJ. ADP receptor antagonism: what's in the pipeline? Am. J. Cardiovasc. Drugs 7, 423-432 (2007).
14. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc. Ther. 27, 259-274 (2009).
15. Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am. Heart J. 156, S10-S15 (2008).
16. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27, 1038-1047 (2006).
17. van Giezen JJ, Nilsson L, Berntsson P et al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J. Thromb. Haemost. 7, 1556-1565 (2009).
18. van Giezen JJ, Berntsson P, Wissing BM. Direct oral P2Y12 receptor antagonist AZD6140 potently and reversibly binds to the rh-P2Y12 receptor expressed on CHO-K1 cells. Arterioscler. Thromb. Vasc. Biol. 28, e72 (2008).
19. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Sem. Thromb. Hemost. 31, 195-204 (2005).
20. Patil SBG, Norman KE, Robins SJ et al. Inhibition of thrombosis by AZD6140 via selective blockade of the P2Y12 receptor in a murine laser-injury model. J. Thromb. Haemost. 5, PW632 (2007).
21. van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA. Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thrombosis Research 124, 565-571 (2009).
22. Ingall AH, Dixon J, Bailey A et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J. Med. Chem. 42, 213-220 (1999).
23. Leff P, Robertson MJ, Humphries RG. The role of ADP in thrombosis and the therapeutic potential of P2T-receptor antagonists as novel antithrombotic agents. In: Purinergic Approaches in Experimental Therapeutics. Jacobson A, Jarvis MF (Eds). Wiley-Liss, NY, USA, 203-216 (1997).
24. Humphries RG, Nicol AK, Tomlinson W et al. Effect of the novel P2T receptor antagonist, AR-C69931MX, on thrombosis and haemostasis in the dog: comparison with GPIIb/IIIa antagonists. Haematologica 85, 91-92 (2000).
25. Peters G, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD6140 - an oral reversible ADP receptor antagonist. Haematologica 989, 14-15 (2004).
26. Peters GR, Butler KA, Winter HR. Multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZP6140. Eur. Heart J. 27, P4556 (2006).
27. Cannon CP, Husted S, Harrington RA et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol. 50, 1844-1851 (2007).
28. Storey RF, Husted S, Harrington RA et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 50, 1852-1856 (2007).
29. Gurbel P, Bliden K, Butler K et al. A randomized double-blind study to assess the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. Circulation 120, S1143 (2009).
30. Bliden K, Tantry U, Antonino M et al. Differential effect of ticagrelor versus clopidogrel on the prevalence of high on-treatment platelet reactivity: results from the ONSET-OFFSET study. Circulation 120, S1172-S1173 (2009).
31. Storey RF, Bliden K, Patil SB. The effect of ticagrelor on cardiopulmonary function in oatients with stable coronary artery disease. Circulation 120, S1145 (2009).
32. Gurbel P, Bliden K, Antonino M. The effect of ticagrelor in stable coronary artery disease patients nonresponsive to clopidogrel: The RESPOND study. Circulation 120, S1173 (2009).
33. James S, Akerblom A, Cannon CP et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J. 157, 599-605 (2009).
34. Wallentin L, Becker RC, Budaj A et al.; PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1-13 (2009).
35. Rao AK, Pratt C, Berke A et al. Thrombolysis in Myocardial Infarction (TIMI) trial - Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J. Am. Coll. Cardiol. 11, 1-11 (1988).
36. Bovill EG, Terrin ML, Stump DC et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II trial. Ann. Intern. Med. 115, 256-265 (1991).
37. Wallentin L, Becker RC, Budaj A et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results from the PLATelet inhibition and patient Outcomes (PLATO) trial. Presented at: American Heart Association 2009. Orlando, FL, USA, 15-18 November 2009 (Final Program Number LBCT.01).
38. Storey RF, Angiolillo DJ, Patil SB. Maintenance treatment with ticagrelor yields greater and more consistent inhibition of platelet function compared to clopidogrel in patients with acute coronary syndromes: results from the PLATO PLATELET substudy. Circulation 120, S1027 (2009).
39. Storey RF, Patil SB, Ecob R. More rapid and consistent inhibition of platelet aggregation is achieved by loading with ticagrelor compared to clopidogrel in patients with acute coronary syndromes: results from the PLATO PLATELET substudy. Circulation 120, S1102 (2009).
40. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation 103, 201-206 (2001).
41. Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am. J. Cardiol. 103(Suppl.), 40A-51A (2009).